Advertisement
UK markets close in 1 hour 3 minutes
  • FTSE 100

    8,449.82
    +4.02 (+0.05%)
     
  • FTSE 250

    20,770.30
    -5.33 (-0.03%)
     
  • AIM

    792.47
    +0.86 (+0.11%)
     
  • GBP/EUR

    1.1655
    +0.0006 (+0.05%)
     
  • GBP/USD

    1.2660
    -0.0024 (-0.19%)
     
  • Bitcoin GBP

    52,040.82
    +1,394.78 (+2.75%)
     
  • CMC Crypto 200

    1,388.37
    -5.67 (-0.41%)
     
  • S&P 500

    5,317.74
    +9.59 (+0.18%)
     
  • DOW

    39,988.13
    +80.13 (+0.20%)
     
  • CRUDE OIL

    79.52
    +0.89 (+1.13%)
     
  • GOLD FUTURES

    2,378.90
    -16.00 (-0.67%)
     
  • NIKKEI 225

    38,920.26
    +534.53 (+1.39%)
     
  • HANG SENG

    19,376.53
    +302.82 (+1.59%)
     
  • DAX

    18,737.90
    -131.46 (-0.70%)
     
  • CAC 40

    8,193.01
    -46.98 (-0.57%)
     

Oculis Publishes Invitation to the Annual General Meeting

Oculis Holding AG
Oculis Holding AG

ZUG, Switzerland, April 29, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis”), today published the invitation to the 2024 Annual General Meeting, which will be held on 29 May 2024 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:30 p.m. CEST / 9:30 a.m. EDT.

All information pertaining to the 2024 Annual General Meeting, including meeting materials, can be accessed on the Oculis website at https://investors.oculis.com‌/events-presentations.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS) purposefully driven to save sight and improve eye care. Oculis’ highly differentiated pipeline comprises multiple innovative product candidates in development. It includes OCS-01, a topical eye drop candidate for diabetic macular edema (DME) and for the treatment of inflammation and pain following cataract surgery; OCS-02 (licaminlimab), a topical biologic anti-TNFα eye drop candidate for dry eye disease (DED) and for non-infectious anterior uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. Headquartered in Switzerland and with operations in the U.S. and Iceland, Oculis’ goal is to deliver life-changing treatments to patients worldwide. The company is led by an experienced management team with a successful track record and is supported by leading international healthcare investors.

ADVERTISEMENT

For more information, please visit: www.oculis.com

Oculis Contacts

Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor & Media Relations

LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
1-212-915-2577